183 related articles for article (PubMed ID: 37605298)
1. Monitoring Metabolic Changes in Response to Chemotherapies in Cancer with Raman Spectroscopy and Metabolomics.
Cutshaw G; Hassan N; Uthaman S; Wen X; Singh B; Sarkar A; Bardhan R
Anal Chem; 2023 Sep; 95(35):13172-13184. PubMed ID: 37605298
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status.
Kato J; Futamura M; Kanematsu M; Gaowa S; Mori R; Tanahashi T; Matsuhashi N; Yoshida K
Int J Cancer; 2016 Mar; 138(6):1516-27. PubMed ID: 26437179
[TBL] [Abstract][Full Text] [Related]
3. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
4. Annexin A3 depletion overcomes resistance to oxaliplatin in colorectal cancer via the MAPK signaling pathway.
Xu R; Yin J; Zhang Y; Zhang S
J Cell Biochem; 2019 Sep; 120(9):14585-14593. PubMed ID: 30998268
[TBL] [Abstract][Full Text] [Related]
5. Tumor-Associated Macrophages Promote Oxaliplatin Resistance
Lan H; Liu Y; Liu J; Wang X; Guan Z; Du J; Jin K
Mol Pharm; 2021 Mar; 18(3):1026-1037. PubMed ID: 33555197
[TBL] [Abstract][Full Text] [Related]
6. TGM2, HMGA2, FXYD3, and LGALS4 genes as biomarkers in acquired oxaliplatin resistance of human colorectal cancer: A systems biology approach.
Cheraghi-Shavi T; Jalal R; Minuchehr Z
PLoS One; 2023; 18(8):e0289535. PubMed ID: 37535601
[TBL] [Abstract][Full Text] [Related]
7. Kaempferol sensitizes cell proliferation inhibition in oxaliplatin-resistant colon cancer cells.
Park J; Lee GE; An HJ; Lee CJ; Cho ES; Kang HC; Lee JY; Lee HS; Choi JS; Kim DJ; Choi JS; Cho YY
Arch Pharm Res; 2021 Dec; 44(12):1091-1108. PubMed ID: 34750753
[TBL] [Abstract][Full Text] [Related]
8. miR-302a Inhibits Metastasis and Cetuximab Resistance in Colorectal Cancer by Targeting NFIB and CD44.
Sun L; Fang Y; Wang X; Han Y; Du F; Li C; Hu H; Liu H; Liu Q; Wang J; Liang J; Chen P; Yang H; Nie Y; Wu K; Fan D; Coffey RJ; Lu Y; Zhao X; Wang X
Theranostics; 2019; 9(26):8409-8425. PubMed ID: 31754405
[No Abstract] [Full Text] [Related]
9. Macranthoidin B Modulates Key Metabolic Pathways to Enhance ROS Generation and Induce Cytotoxicity and Apoptosis in Colorectal Cancer.
Fan X; Rao J; Zhang Z; Li D; Cui W; Zhang J; Wang H; Tou F; Zheng Z; Shen Q
Cell Physiol Biochem; 2018; 46(4):1317-1330. PubMed ID: 29689551
[TBL] [Abstract][Full Text] [Related]
10. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
11. Preclinical studies on metal based anticancer drugs as enabled by integrated metallomics and metabolomics.
Galvez L; Rusz M; Schwaiger-Haber M; El Abiead Y; Hermann G; Jungwirth U; Berger W; Keppler BK; Jakupec MA; Koellensperger G
Metallomics; 2019 Oct; 11(10):1716-1728. PubMed ID: 31497817
[TBL] [Abstract][Full Text] [Related]
12. Campylobacter jejuni Antimicrobial Resistance Profiles and Mechanisms Determined Using a Raman Spectroscopy-Based Metabolomic Approach.
Ma L; Chen L; Chou KC; Lu X
Appl Environ Microbiol; 2021 May; 87(12):e0038821. PubMed ID: 33837016
[TBL] [Abstract][Full Text] [Related]
13. Mass spectrometry-based metabolomics approach and in vitro assays revealed promising role of 2,3-dihydroquinazolin-4(1H)-one derivatives against colorectal cancer cell lines.
Dahabiyeh LA; Hudaib F; Hourani W; Darwish W; Abu-Irmaileh B; Deb PK; Venugopala KN; Mohanlall V; Chandrashekharappa S; Abu-Dahab R; Semreen MH; Bustanji Y
Eur J Pharm Sci; 2023 Mar; 182():106378. PubMed ID: 36638899
[TBL] [Abstract][Full Text] [Related]
14. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer.
Zalba S; Contreras AM; Haeri A; Ten Hagen TL; Navarro I; Koning G; Garrido MJ
J Control Release; 2015 Jul; 210():26-38. PubMed ID: 25998052
[TBL] [Abstract][Full Text] [Related]
15. Wnt/β-catenin signalling activates IMPDH2-mediated purine metabolism to facilitate oxaliplatin resistance by inhibiting caspase-dependent apoptosis in colorectal cancer.
Huang Y; Chan S; Chen S; Liu X; Li M; Zheng L; Dong Z; Yang Z; Liu Z; Zhou D; Zhang X; Zhang B
J Transl Med; 2024 Feb; 22(1):133. PubMed ID: 38310229
[TBL] [Abstract][Full Text] [Related]
16. Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin.
Narvi E; Vaparanta K; Karrila A; Chakroborty D; Knuutila S; Pulliainen A; Sundvall M; Elenius K
Sci Rep; 2018 Nov; 8(1):16579. PubMed ID: 30410004
[TBL] [Abstract][Full Text] [Related]
17. Systems analysis identifies potential target genes to overcome cetuximab resistance in colorectal cancer cells.
Park SM; Hwang CY; Cho SH; Lee D; Gong JR; Lee S; Nam S; Cho KH
FEBS J; 2019 Apr; 286(7):1305-1318. PubMed ID: 30719834
[TBL] [Abstract][Full Text] [Related]
18. Metabolic profiling disturbance of PM
Liu D; Liu Y; Wang R; Feng L; Xu L; Jin C
Environ Sci Pollut Res Int; 2022 Oct; 29(49):74500-74511. PubMed ID: 35639313
[TBL] [Abstract][Full Text] [Related]
19. Lemur tyrosine kinase-3 (LMTK3) induces chemoresistance to cetuximab in colorectal cancer via the ERK/MAPK pathway.
Wang C; Yang M; Gu X; Gu Y
Bioengineered; 2021 Dec; 12(1):6594-6605. PubMed ID: 34516351
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
